雷特格韦钾盐 T2239

Product Introduction
Bioactivity


英文名: Raltegravir potassium

描述: Raltegravir potassium (MK 0518 potassium salt) 是一种整合酶抑制剂，用于研究 HIV 感染。

细胞实验: Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 105/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM-1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37°C, the formation of new clusters is assessed by light microscopy (100× magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection.

体外活性: PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM which indicates an appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme[1]. Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity[2]. Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium[3]. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication[4]. SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range in acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174[5].

体内活性: Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate exhibits an undetectable viral load following Raltegravir monotherapy[5].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 87 mg/mL(180.3 mM)


关键字: Raltegravir | inhibit | HIV | Inhibitor | MK 0518 | Human immunodeficiency virus | MK-0518 | MK0518 | HIV Integrase | Raltegravir potassium | MK 0518 potassium

相关产品: ML67-33 | Liquidambaric lactone | CK-666 | 5-Hydroxy-7,8-dimethoxyflavanone | (+)-Nortrachelogenin | Coronalolide methyl ester | lavendustin B | Rottlerin | Protosappanin A | Isoapetalic acid

相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Inhibitor Library | Pediatric Drug Library | Highly Selective Inhibitor Library | PPI Inhibitor Library | EMA Approved Drug Library | Orally Active Compound Library | Anti-Viral Compound Library

雷特格韦钾盐 T2239信息由TargetMol中国为您提供，如您想了解更多关于雷特格韦钾盐 T2239报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途